Fundraising FoxNuvision Biotherapies
Nottingham, GB · 1 known investors
Find your way into Nuvision Biotherapies
Sign up to see every warm intro you have to Nuvision Biotherapies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuvision Biotherapies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NuVision develops ocular biotherapies rooted in translational research from the University of Nottingham, aiming to provide patients with immediate access to innovative eye surface repair and regeneration treatments. The company operates across the UK, Middle East, Nordics, and central Europe.
Founders & leadership
AH
Andrew HopkinsonChief Scientific Officer, FounderAndrew Hopkinson is Chief Scientific Officer and founder of NuVision Biotherapies, an ocular biotherapies company, and holds an Honorary Principal Research Fellow position in Ocular Surface Regenerative Medicine at the University of Nottingham's Department of Academic Ophthalmology. He has a background in molecular biology and translational research focused on regenerative medicine technologies.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- NUVISION BIOTHERAPIES LIMITED
- Company number
- 09526225
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Apr 2015
- Registered office
- Medicity, D6 Building, Thane Road, Nottingham, NG90 6BH
- Nature of business (SIC)
- 21200 — Manufacture of pharmaceutical preparations
- Previous names
- NU VISION BIOTHERAPIES LIMITED (2015–2015)
- Accounts
- last made up to 30 Jun 2025 · next due 31 Mar 2027
- Confirmation statement
- last made up to 11 Feb 2026 · next due 25 Feb 2027
Current officers · 6
- Timothy John Gray — director, appointed 19 Jun 2025
- Andrew Hopkinson — director, appointed 20 May 2015
- Timothy James Precious — director, appointed 26 May 2026
- Roger Peter Teasdale — director, appointed 1 Mar 2018
- Noel Waters — director, appointed 19 Jun 2025
- Mercia Fund Management (nominees) Limited — corporate director, appointed 26 Nov 2020
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Nuvision Biotherapies do?
- NuVision develops ocular biotherapies rooted in translational research from the University of Nottingham, aiming to provide patients with immediate access to innovative eye surface repair and regeneration treatments. The company operates across the UK, Middle East, Nordics, and central Europe.
- Who founded Nuvision Biotherapies?
- Nuvision Biotherapies was founded by Andrew Hopkinson.
- Who are Nuvision Biotherapies's investors?
- Nuvision Biotherapies's investors include Maven Capital Partners.
- Where is Nuvision Biotherapies headquartered?
- Nuvision Biotherapies is headquartered in Nottingham, GB.